201 related articles for article (PubMed ID: 14695148)
1. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms.
Yakirevich E; Sabo E; Lavie O; Mazareb S; Spagnoli GC; Resnick MB
Clin Cancer Res; 2003 Dec; 9(17):6453-60. PubMed ID: 14695148
[TBL] [Abstract][Full Text] [Related]
2. Cancer-testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomas.
Resnick MB; Sabo E; Kondratev S; Kerner H; Spagnoli GC; Yakirevich E
Int J Cancer; 2002 Sep; 101(2):190-5. PubMed ID: 12209997
[TBL] [Abstract][Full Text] [Related]
3. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease.
Dhodapkar MV; Osman K; Teruya-Feldstein J; Filippa D; Hedvat CV; Iversen K; Kolb D; Geller MD; Hassoun H; Kewalramani T; Comenzo RL; Coplan K; Chen YT; Jungbluth AA
Cancer Immun; 2003 Jul; 3():9. PubMed ID: 12875607
[TBL] [Abstract][Full Text] [Related]
4. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.
Odunsi K; Jungbluth AA; Stockert E; Qian F; Gnjatic S; Tammela J; Intengan M; Beck A; Keitz B; Santiago D; Williamson B; Scanlan MJ; Ritter G; Chen YT; Driscoll D; Sood A; Lele S; Old LJ
Cancer Res; 2003 Sep; 63(18):6076-83. PubMed ID: 14522938
[TBL] [Abstract][Full Text] [Related]
5. Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma.
Sugita M; Geraci M; Gao B; Powell RL; Hirsch FR; Johnson G; Lapadat R; Gabrielson E; Bremnes R; Bunn PA; Franklin WA
Cancer Res; 2002 Jul; 62(14):3971-9. PubMed ID: 12124329
[TBL] [Abstract][Full Text] [Related]
6. Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma.
Kienstra MA; Neel HB; Strome SE; Roche P
Head Neck; 2003 Jun; 25(6):457-63. PubMed ID: 12784237
[TBL] [Abstract][Full Text] [Related]
7. Expression and clinical relevance of NY-ESO-1, MAGE-1 and MAGE-3 in neuroblastoma.
Söling A; Schurr P; Berthold F
Anticancer Res; 1999; 19(3B):2205-9. PubMed ID: 10472332
[TBL] [Abstract][Full Text] [Related]
8. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer.
Akcakanat A; Kanda T; Koyama Y; Watanabe M; Kimura E; Yoshida Y; Komukai S; Nakagawa S; Odani S; Fujii H; Hatakeyama K
Cancer Chemother Pharmacol; 2004 Jul; 54(1):95-100. PubMed ID: 15118836
[TBL] [Abstract][Full Text] [Related]
9. NY-ESO-1 protein expression and humoral immune responses in prostate cancer.
Fosså A; Berner A; Fosså SD; Hernes E; Gaudernack G; Smeland EB
Prostate; 2004 Jun; 59(4):440-7. PubMed ID: 15065093
[TBL] [Abstract][Full Text] [Related]
10. Immunomic analysis of human sarcoma.
Lee SY; Obata Y; Yoshida M; Stockert E; Williamson B; Jungbluth AA; Chen YT; Old LJ; Scanlan MJ
Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2651-6. PubMed ID: 12601173
[TBL] [Abstract][Full Text] [Related]
11. Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma.
Bolli M; Kocher T; Adamina M; Guller U; Dalquen P; Haas P; Mirlacher M; Gambazzi F; Harder F; Heberer M; Sauter G; Spagnoli GC
Ann Surg; 2002 Dec; 236(6):785-93; discussion 793. PubMed ID: 12454517
[TBL] [Abstract][Full Text] [Related]
12. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas.
Mashino K; Sadanaga N; Tanaka F; Yamaguchi H; Nagashima H; Inoue H; Sugimachi K; Mori M
Br J Cancer; 2001 Sep; 85(5):713-20. PubMed ID: 11531257
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of HLA-DR antigen in serous ovarian tumors.
Tamiolakis D; Kotini A; Venizelos J; Jivannakis T; Simopoulos C; Papadopoulos N
Clin Exp Med; 2003 Sep; 3(2):113-8. PubMed ID: 14598186
[TBL] [Abstract][Full Text] [Related]
14. [Expression of multiple cancer-testis antigen genes in non-small cell lung cancer treated by chemotherapy prior surgery].
Wang Y; Liang Z; Yuan YH; Han Y; Liu YX; Liu N; Chen YT; Ritter G; Old LJ; Zhang LJ
Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(6):464-8. PubMed ID: 15061963
[TBL] [Abstract][Full Text] [Related]
15. MAGE-1 and MAGE-3 tumor rejection antigens in human germ cell tumors.
Cheville JC; Roche PC
Mod Pathol; 1999 Oct; 12(10):974-8. PubMed ID: 10530563
[TBL] [Abstract][Full Text] [Related]
16. NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma.
Goydos JS; Patel M; Shih W
J Surg Res; 2001 Jun; 98(2):76-80. PubMed ID: 11397121
[TBL] [Abstract][Full Text] [Related]
17. [Expression of tumor-specific cancer/testis antigens in hepatocellular carcinoma].
Chen HS; Qin LL; Cong X; Wang Y; Fei R; Jiang D; Cao J; Su JJ; Wei L; Chen WF; Wang Y
Zhonghua Gan Zang Bing Za Zhi; 2003 Mar; 11(3):145-8. PubMed ID: 12681059
[TBL] [Abstract][Full Text] [Related]
18. [Sharing antigenic determinant of colon carcinoma between serous and mucinous tumors of the ovary].
Liu MP; Lu ZT; Chen W
Zhonghua Fu Chan Ke Za Zhi; 1994 Jul; 29(7):398-400, 444. PubMed ID: 7528120
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of laminin-5 in serous adenocarcinomas of the ovary.
Kohlberger P; Muller-Klingspor V; Heinzl H; Obermair A; Breitenecker G; Leodolter S
Anticancer Res; 2002; 22(6B):3541-4. PubMed ID: 12552953
[TBL] [Abstract][Full Text] [Related]
20. Expression of Fas and FasL in human serous ovarian epithelial tumors.
van Haaften-Day C; Russell P; Davies S; King NJ; Tattersall MH
Hum Pathol; 2003 Jan; 34(1):74-9. PubMed ID: 12605369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
